¼ö¿ëü ¡í
GPCR ¡í
µ¶°ú¾à ¡í
Shape
drug design(ÇüÅÂ,¿ëÇصµ)
drug design :
µ¶°ú¾à
-
½Å¾à °³¹ß È®·ü
-
GPCR ¿ªÇÒ :
½Å¾à °³¹ßÀÇ µ¹Æı¸ : ¾à¹° ÀÛ¿ëÀÇ Àý¹Ý
-
¾àÀÇ ºÐÀÚÇüÅ QSAR
-
°í¾Æ GPCR
- ºÐÀÚ·® :
- ¿ëÇصµ :
1. Natural Products: MW ~400-1000
Structurally highly diverse, Often biologically active
Optimization process is time consuming, High manufacturing costs
2. Synthetic compounds collections: M.W ~300-350.
Drug-like, Structural diversity is limited
Optimization process straightforward, Low manufacturing costs
3. Peptoids, peptides and peptidomimetics derived from a target protein : M.W >600
Fast assembly through linear assembly of similar¡¤building blocks
Limited,¡°rather flexible¡± diversity.
Usually not ¡°drug-like¡±, Optimization process often long and tedious
4. Small-molecular-weight compound libraries from combinatorial and parallel chemistry: Molecular weight <600.
Fast and convergent assembly using reactive building blocks
Limited chemica1and structural diversity
¡°Drug-like¡±, Fast optimization process, Low manufactoring costs